Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

673
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
673
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Declines in Social Support During Breast Cancer Treatment and Their Association With Exercise Capacity Reductions in Breast Cancer Survivors.

American journal of lifestyle medicine·2026
Same author

Cardiac remodelling and dysfunction in cancer patients receiving cardiotoxic therapies: proteomic and metabolomic profiling.

European heart journal·2026
Same author

Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study.

JACC. Advances·2026
Same author

Atrial Fibrillation Risk and Cardiovascular Events After Hematopoietic Cell Transplantation: A Prospective Cohort Study.

JACC. CardioOncology·2026
Same author

In Memoriam: Dr Eugene Braunwald, MD, MACC.

JACC. CardioOncology·2026
Same author

STING promotes CD8 T-cell cardiotropism and fibrosis from distinct cellular compartments in doxorubicin cardiomyopathy.

Cardiovascular research·2026

Video Experimental Relacionado

Updated: Sep 9, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K

Atorvastatina y la función auricular izquierda durante la quimioterapia con antraciclina

Vencel Juhasz1, Zsofia D Drobni2, Thiago Quinaglia3

  • 1Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.

Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
|August 28, 2025
PubMed
Resumen

La atorvastatina no impidió la disminución de la tensión auricular izquierda en pacientes con linfoma que recibieron antraciclinas. Este estudio no encontró diferencias significativas en la función auricular izquierda entre los grupos de atorvastatina y placebo.

Palabras clave:
Disfunción cardíacaDisfunción cardíaca relacionada con el tratamiento del cáncerResonancia magnética cardíacaseguimiento de característicasEstirpe de miocardio

Más Videos Relacionados

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.5K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Área de la Ciencia:

  • Cardiología
  • En el campo de la oncología
  • Farmacología

Sus antecedentes:

  • Las anomalías estructurales y funcionales de la aurícula izquierda están relacionadas con resultados adversos en enfermedades cardíacas.
  • El impacto de las antraciclinas en la estructura y la función de LA no se comprende completamente.
  • Se conoce el efecto protector de la atorvastatina sobre la fracción de eyección ventricular izquierda frente a las antraciclinas, pero su efecto sobre la AL no está claro.

Objetivo del estudio:

  • Investigar si la atorvastatina mitiga el deterioro inducido por la antraciclina de la estructura y la función de la aurícula izquierda.
  • Evaluar el efecto de la atorvastatina en la tensión de LA y las mediciones volumétricas en pacientes sometidos a quimioterapia con antraciclina.

Principales métodos:

  • El ensayo clínico aleatorizado STOP- CA incluyó a pacientes con linfoma tratados con antraciclinas.
  • Los participantes fueron asignados al azar para recibir placebo o atorvastatina durante 12 meses.
  • Las mediciones volumétricas y funcionales de LA derivadas de la resonancia magnética cardiovascular (CMR), incluida la tensión longitudinal global (GLS), se evaluaron al inicio y a los 12 meses utilizando el seguimiento de las características.

Principales resultados:

  • No se observaron diferencias significativas en la proporción de participantes que experimentaron una disminución relativa de ≥1 SD o ≥20% en LA GLS entre los grupos de atorvastatina y placebo.
  • Se observó una disminución de LA GLS en el grupo placebo desde el inicio hasta el seguimiento.
  • Los participantes mayores de 50 años mostraron una mayor disminución relativa de LA GLS con antraciclinas, independientemente del tratamiento con atorvastatina.

Conclusiones:

  • La atorvastatina no atenuó la disminución del LA GLS derivado de la CMR en pacientes con linfoma tratados con quimioterapia basada en antraciclina.
  • El estudio sugiere que la atorvastatina no protege contra el deterioro asociado a la antraciclina de la función auricular izquierda.